Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms.

JoAnn V. Pinkerton, Redick DL, Homewood LN, Kaunitz AM
The Journal of clinical endocrinology and metabolism · 2023 · doi:10.1210/clinem/dgad209 · PMID:37097747 · PMC10583986
OA: gold CC-BY-NC-ND-4.0
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash+body, 2026-08-22 ⓘ

This paper discusses the neurokinin receptor antagonist fezolinetant as a treatment for menopausal vasomotor symptoms and discloses financial relationships among authors with Merck, Mithra Pharmaceuticals, Pfizer, and Bayer.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-22 · read from full text ⓘ

This review article evaluates the efficacy and safety of fezolinetant, a neurokinin-3 receptor antagonist, for managing menopausal vasomotor symptoms. The authors summarize clinical trial data demonstrating that the drug significantly reduces the frequency of hot flashes by targeting the hypothalamic thermoregulatory center, offering a non-hormonal treatment option. They also discuss potential side effects, including elevated liver enzymes, which necessitates monitoring during therapy. Relevance to endometriosis: listed as one indication for GnRH antagonists, though the paper's main focus is uterine fibroids.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 967 characters · extracted from epmc-fulltextxml · 2 sections · click to expand

Disclosures

A.M.K. has served on the advisory board for Merck, Mithra Pharmaceuticals, and Pfizer. The University of Florida College of Medicine receives research funding from Merck and Bayer for ongoing clinical trials; J.V.P. Bayer Pharmaceuticals Multicenter Research Trial; fees to the University of Virginia; D.L.R. has nothing to disclose; L.N.H. has nothing to disclose.

Contrib Info

JoAnn V Pinkerton, Department of Obstetrics and Gynecology, Division of Midlife Health, University of Charlottesville, Charlottesville, VA 22908, USA. Dana L Redick, Department of Obstetrics and Gynecology, Division of Midlife Health, University of Charlottesville, Charlottesville, VA 22908, USA. Laura N Homewood, Department of Obstetrics and Gynecology Division of Minimally Invasive Gynecologic Surgery, University of Virginia, Charlottesville, VA, USA. Andrew M Kaunitz, Department of Obstetrics and Gynecology, University of Florida College of Medicine- Jacksonville, Jacksonville, FL, USA.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: epmc-fulltextxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-04T09:26:46.659050+00:00
unpaywall
last seen: 2026-08-13T06:47:16.638238+00:00
License: CC-BY-NC-ND-4.0